A Phase 1 interventional study of TAK-951 Placebo and TAK-951 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-14.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a study of TAK-951 for people with symptoms of nausea and vomiting. The main aims of this study in healthy adults are as follows:
Participants will receive a single infusion of either TAK-951 or placebo. In this study, a placebo looks like TAK-951 but does not have any medicine in it. Participants will receive either a low dose or high dose of TAK-951. The infusion will take from 1-3 hours.
Participants will stay in the study clinic for about 4 days to receive the study medicine (TAK-951 or placebo) and check for side effects. They will have follow-up visits at the clinic about 2 weeks and 4 weeks after treatment.
The drug being tested in this study is called TAK-951. The study evaluated the safety, tolerability and pharmacokinetics (PK) of TAK-951 in healthy participants.
The study enrolled 128 healthy participants and consisted of 2 parts: Single-rising Dose (SRD) part (13 cohorts) of sequential panel design, and Multiple-rising Dose (MRD) part (5 cohorts) of sequential panel design. Participants in each cohort were randomized to receive treatment with TAK-951 or matching placebo using SC injection, once daily on Day 1 (for SRD part) and twice daily (BID) on Days 1 through 5 (for MRD part) following a minimum fast of 8 hours.
This single center trial was conducted in the United States. The overall time to participate in this study was approximately 155 days.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-951 placebo-matching, single dose, subcutaneous (SC) injection, on Day 1 in fasted healthy participants in the single-rising dose (SRD) period.
Drug: TAK-951 Placebo
TAK-951 Dose 1, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 2, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 2, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 3, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 4, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 5, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 6, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 7, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 8, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 9, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 10, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 Dose 11, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
Drug: TAK-951
TAK-951 placebo-matching, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the multiple-rising dose (MRD) period.
Drug: TAK-951 Placebo
TAK-951 Dose 1A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
Drug: TAK-951
TAK-951 Dose 2A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
Drug: TAK-951
TAK-951 Dose 3A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
Drug: TAK-951
TAK-951 Dose 4A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
Drug: TAK-951
TAK-951 placebo-matching SC injection
TAK-951 SC injection
Parts 1 and 3: Percentage of Participants With Clinically Significant Physical Examination Findings
Physical examination included the examination of the abdomen; extremities; head, eyes, ears, nose (HEENT); neurological; skin and mucosae; thorax.
Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of Vital Signs Parameters
The criteria for markedly abnormal values of vital signs' parameters were: Pulse Rate (beats/minute) \<50 and \>120; Systolic Blood Pressure \[millimeters of mercury (mmHg)\] \<85 and \>180; Diastolic Blood Pressure (mmHg) \<50 and \>110; Temperature \[degrees Celsius (C)\] \<35.6 and \>37.7. Only categories with atleast one participant with events are reported.
Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters
The criteria for markedly abnormal values of 12-lead ECG parameters were: ECG Mean Heart Rate (beats/min) \<50 beats per minute and \>120 beats per minute; PR Interval, Aggregate \[milliseconds (msec)\] \<=80 msec and \>=200 msec; QRS Duration, Aggregate (msec) \<=80 msec and \>=120 msec; QT Interval with Fridericia Correction Method (QTcF) Interval, Aggregate (msec) \>=500 msec or \>=30 msec change from Baseline and \>=450 msec. Only categories with atleast one participant with event are reported.
Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of Laboratory Parameters
The laboratory parameters of chemistry, and hematology were assessed. Clinical laboratory tests included serum chemistry, hematology, and urinalysis. MAV criteria: Alanine aminotransferase(U/L) \>3xupper limit of normal(ULN); Albumin\<2.5g/dL,\<25g/L; Alkaline phosphatase (U/L)\>3 x ULN; Aspartate aminotransferase (U/L)\>3 x ULN; Bilirubin\>1.5mg/dL, \>34.2 µmol/L; Calcium\<8.0 mg/dL,LLN-\<2.0mmol/L, \>1.0mmol/L; Carbon dioxide \<8.0 (mmol/L); Chloride\<75 mmol/L,\>126 mmol/L; Creatinine\>177µmol/L; Gamma glutamyl transferase (U/L)\>2.0 mg/dL, \>3.0 x ULN; Glucose\<3 mmol/L,\>10 mmol/L; Potassium\<3.0 mmol/L \>5.5 mmol/L; Protein(g/L)\<0.8 x LLN \>1.2 x ULN; Sodium\<130mmol/L \>150mmol/L; Urea nitrogen \>10.7; Erythrocytes 10\^12erythrocytes/L) \<0.8 x LLN,\>1.2 x ULN; Hematocrit(%) \<0.8 x LLN,\>1.2xULN; Hemoglobin(g/L)\<0.8 x LLN, \>1.2 x ULN; Leukocytes(10\^9 leukocytes/L)\<0.5 x LLN \>1.5 x ULN; platelets(10\^9 platelets/L)\<75-\>600. Only categories with atleast one participant with event are reported.
Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Parts 1 and 3: Percentage of Participants With Treatment-Emergent Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event which occurred on or after the first dose of study drug and no more than 30 days after the last dose of study drug.
Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Parts 1 and 3: Percentage of Participants With Positive Immunogenicity (ADA) Status
Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Part 1: Cmax: Maximum Observed Plasma Concentration for TAK-951
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Part 1
Part 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Part 1
Part 3: Cmax: Maximum Observed Plasma Concentration for TAK-951 on Day 1
Time frame: Pre-dose and at multiple time points (up to 24 hours) post-dose on Day 1 in Part 3
Part 3: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval Tau (τ), From Time of First Daily Dose to 8 Hours for TAK-951 on Day 1
Time frame: Pre-dose and at multiple time points (up to 24 hours) post-dose on Day 1 in Part 3
Participants took part in the study at 1 investigative site in the United States from 07 March 2019 to 02 November 2020.
| Milestone | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 24 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 8 | 6 | 6 | 6 | 6 |
| Completed | 24 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Physical examination included the examination of the abdomen; extremities; head, eyes, ears, nose (HEENT); neurological; skin and mucosae; thorax.
| percentage of participants | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 3: Percentage of Participants With Clinically Significant Physical Examination Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The criteria for markedly abnormal values of vital signs' parameters were: Pulse Rate (beats/minute) \<50 and \>120; Systolic Blood Pressure \[millimeters of mercury (mmHg)\] \<85 and \>180; Diastolic Blood Pressure (mmHg) \<50 and \>110; Temperature \[degrees Celsius (C)\] \<35.6 and \>37.7. Only categories with atleast one participant with events are reported.
| percentage of participants | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diastolic Blood Pressure (mmHg) <50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 16.7 | 33.3 | 16.7 | 16.7 | 16.7 | 0 | 0 | 16.7 | 0 | 0 |
| Pulse Rate (beats/minute) <50 | 8.3 | 16.7 | 0 | 16.7 | 16.7 | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50.0 | 50.0 | 50.0 | 0 | 33.3 |
| Pulse Rate (beats/minute) >120 | 0 | 0 | 0 | 0 | 0 | 0 | 33.3 | 0 | 16.7 | 16.7 | 50.0 | 50.0 | 16.7 | 0 | 0 | 50.0 | 16.7 | 16.7 |
| Systolic Blood Pressure (mmHg) <85 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 33.3 | 16.7 | 16.7 | 0 | 12.5 | 0 | 33.3 | 0 | 0 |
| Temperature (C) <35.6 | 4.2 | 33.3 | 16.7 | 0 | 16.7 | 16.7 | 16.7 | 0 | 0 | 16.7 | 0 | 0 | 16.7 | 25.0 | 33.3 | 16.7 | 16.7 | 16.7 |
The criteria for markedly abnormal values of 12-lead ECG parameters were: ECG Mean Heart Rate (beats/min) \<50 beats per minute and \>120 beats per minute; PR Interval, Aggregate \[milliseconds (msec)\] \<=80 msec and \>=200 msec; QRS Duration, Aggregate (msec) \<=80 msec and \>=120 msec; QT Interval with Fridericia Correction Method (QTcF) Interval, Aggregate (msec) \>=500 msec or \>=30 msec change from Baseline and \>=450 msec. Only categories with atleast one participant with event are reported.
| percentage of participants | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ECG Mean Heart Rate (beats/minute) <50 | 8.3 | 0 | 0 | 16.7 | 16.7 | 33.3 | 0 | 16.7 | 16.7 | 0 | 16.7 | 16.7 | 0 | 37.5 | 0 | 33.3 | 0 | 16.7 |
| PR Interval, Aggregate (msec) >=200 | 4.2 | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 | 0 |
| QRS Duration, Aggregate (msec) <=80 | 20.8 | 16.7 | 16.7 | 16.7 | 16.7 | 0 | 33.3 | 16.7 | 0 | 16.7 | 16.7 | 16.7 | 16.7 | 0 | 0 | 33.3 | 16.7 | 16.7 |
The laboratory parameters of chemistry, and hematology were assessed. Clinical laboratory tests included serum chemistry, hematology, and urinalysis. MAV criteria: Alanine aminotransferase(U/L) \>3xupper limit of normal(ULN); Albumin\<2.5g/dL,\<25g/L; Alkaline phosphatase (U/L)\>3 x ULN; Aspartate aminotransferase (U/L)\>3 x ULN; Bilirubin\>1.5mg/dL, \>34.2 µmol/L; Calcium\<8.0 mg/dL,LLN-\<2.0mmol/L, \>1.0mmol/L; Carbon dioxide \<8.0 (mmol/L); Chloride\<75 mmol/L,\>126 mmol/L; Creatinine\>177µmol/L; Gamma glutamyl transferase (U/L)\>2.0 mg/dL, \>3.0 x ULN; Glucose\<3 mmol/L,\>10 mmol/L; Potassium\<3.0 mmol/L \>5.5 mmol/L; Protein(g/L)\<0.8 x LLN \>1.2 x ULN; Sodium\<130mmol/L \>150mmol/L; Urea nitrogen \>10.7; Erythrocytes 10\^12erythrocytes/L) \<0.8 x LLN,\>1.2 x ULN; Hematocrit(%) \<0.8 x LLN,\>1.2xULN; Hemoglobin(g/L)\<0.8 x LLN, \>1.2 x ULN; Leukocytes(10\^9 leukocytes/L)\<0.5 x LLN \>1.5 x ULN; platelets(10\^9 platelets/L)\<75-\>600. Only categories with atleast one participant with event are reported.
| percentage of participants | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium(mmol/L):Corrected Serum Calcium <LLN 8.0mg/dL;<LLN 2.0mmol/L;Ionized calcium<LLN 1.0mmol/L | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 |
| Glucose (mmol/L) >10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 0 |
| Urea Nitrogen (mmol/L) >10.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.5 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event which occurred on or after the first dose of study drug and no more than 30 days after the last dose of study drug.
| percentage of participants | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 3: Percentage of Participants With Treatment-Emergent Adverse Events | 16.7 | 16.7 | 16.7 | 16.7 | 16.7 | 16.7 | 33.3 | 50.0 | 50.0 | 83.3 | 66.7 | 83.3 | 33.3 | 37.5 | 16.7 | 83.3 | 66.7 | 83.3 |
| percentage of participants | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1 and 3: Percentage of Participants With Positive Immunogenicity (ADA) Status | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 |
| picograms per milliliters (pg/mL) | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Cmax: Maximum Observed Plasma Concentration for TAK-951 | 177 ± 22.3 | 213 ± 35.4 | 420 ± 14.4 | 383 ± 20.0 | 717 ± 29.0 | 2070 ± 24.7 | 3010 ± 38.4 | 4230 ± 32.4 | 8920 ± 41.7 | 8540 ± 23.6 | 27900 ± 19.3 | 54300 ± 14.1 |
| picograms*hour per milliliters(pg*hr/mL) | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951 | 813 ± 14.6 | — | 1960 ± 8.50 | — | 3920 ± 12.3 | 9230 ± 25.7 | 15300 ± 14.0 | 21700 ± 34.4 | 46700 ± 23.3 | 50700 ± 25.7 | 140000 ± 17.8 | 340000 ± 20.8 |
| pg/mL | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|
| Part 3: Cmax: Maximum Observed Plasma Concentration for TAK-951 on Day 1 | 1260 ± 27.1 | 6010 ± 18.2 | 22400 ± 25.8 | 33700 ± 24.6 |
| pg*hr/mL | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|
| Part 3: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval Tau (τ), From Time of First Daily Dose to 8 Hours for TAK-951 on Day 1 | 5420 ± 25.2 | 25000 ± 15.9 | 98100 ± 22.8 | 152000 ± 29.4 |
Collected over From first dose of study drug and up to 30 days post last dose (Parts 1 and 3: Up to approximately 32 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 (SRD): Pooled Placebo | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 3 (MRD): Pooled Placebo | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ventricular tachycardiaCardiac disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 0/6 | 0/6 |
| Event | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 2/6 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 2/6 | 0/6 |
| DizzinessNervous system disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 1/6 | 1/6 | 0/6 | 2/8 | 0/6 | 2/6 | 2/6 | 1/6 |
| Dizziness posturalNervous system disorders | 0/24 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 1/6 | 0/6 | 1/6 | 0/8 | 0/6 | 2/6 | 0/6 | 0/6 |
| HeadacheNervous system disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/8 | 0/6 | 2/6 | 2/6 | 1/6 |
| NauseaGastrointestinal disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 2/6 | 2/6 |
| Orthostatic hypotensionVascular disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 1/6 | 0/6 | 0/8 | 0/6 | 2/6 | 0/6 | 0/6 |
| PalpitationsCardiac disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 1/6 | 2/6 | 1/6 | 0/6 | 0/8 | 1/6 | 1/6 | 0/6 | 1/6 |
| Postural orthostatic tachycardia syndromeCardiac disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 2/6 | 0/6 | 0/8 | 0/6 | 0/6 | 0/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/24 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 1/6 | 0/6 |
Safety Set included all randomized participants who received at least 1 dose of investigational products in each part of the study.
| Age, Continuous(years) | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 39.4 (21 to 53) | 35.2 (24 to 42) | 40.0 (28 to 48) | 35.5 (26 to 41) | 41.8 (21 to 52) | 35.2 (23 to 53) | 34.8 (24 to 48) | 32.0 (24 to 43) | 38.7 (28 to 50) | 42.2 (27 to 52) | 34.5 (26 to 49) | 27.8 (20 to 37) | 43.0 (30 to 53) | 37.3 (27 to 48) | 35.2 (27 to 44) | 33.2 (23 to 39) | 41.3 (36 to 48) | 40.3 (31 to 52) | 37.4 (20 to 53) |
| Sex: Female, Male(Participants) | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 11 |
| Male | 21 | 5 | 6 | 5 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 7 | 5 | 5 | 6 | 6 | 117 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 0 | 4 | 2 | 36 |
| Not Hispanic or Latino | 18 | 6 | 5 | 5 | 5 | 4 | 6 | 5 | 4 | 3 | 3 | 4 | 3 | 4 | 4 | 6 | 2 | 4 | 91 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 13 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 0 | 1 | 2 | 1 | 4 | 2 | 1 | 0 | 3 | 41 |
| White | 9 | 2 | 3 | 4 | 3 | 4 | 3 | 3 | 3 | 5 | 3 | 3 | 5 | 4 | 3 | 4 | 5 | 3 | 69 |
| More than one race | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 8 |
| Region of Enrollment(Participants) | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 24 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 8 | 6 | 6 | 6 | 6 | 128 |
| Weight(kg) | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 81.20 (59.8 to 106.7) | 78.88 (68.4 to 87.8) | 81.45 (64.1 to 96.2) | 74.10 (65.4 to 90.8) | 73.27 (55.4 to 88.9) | 76.65 (64.1 to 93.6) | 80.02 (60.9 to 107.1) | 76.27 (60.2 to 86.0) | 81.27 (76.2 to 86.5) | 78.87 (65.0 to 87.6) | 77.88 (66.1 to 87.5) | 75.17 (57.1 to 86.5) | 74.92 (59.8 to 88.1) | 78.64 (61.8 to 95.0) | 77.68 (65.0 to 88.8) | 76.35 (64.9 to 93.0) | 75.73 (61.5 to 93.1) | 83.75 (71.3 to 97.8) | 77.89 (55.4 to 107.1) |
| Height(cm) | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 176.8 (162 to 195) | 174.3 (170 to 183) | 175.7 (170 to 184) | 177.8 (161 to 184) | 174.5 (164 to 194) | 177.2 (170 to 183) | 182.5 (174 to 193) | 173.8 (169 to 185) | 175.5 (173 to 182) | 174.0 (162 to 186) | 174.0 (158 to 179) | 172.5 (167 to 176) | 175.8 (165 to 189) | 175.3 (158 to 194) | 172.0 (162 to 181) | 174.7 (163 to 185) | 169.3 (160 to 179) | 175.0 (166 to 181) | 175.04 (158 to 195) |
| Body Mass Index (BMI)(kg/m^2) | Part 1 (SRD): Pooled Placebo | Part 1 (SRD): Cohort 2: TAK-951 Dose 1 | Part 1 (SRD): Cohort 1: TAK-951 Dose 2 | Part 1 (SRD): Cohort 15: TAK-951 Dose 2 | Part 1 (SRD): Cohort 3: TAK-951 Dose 3 | Part 1 (SRD): Cohort 4: TAK-951 Dose 4 | Part 1 (SRD): Cohort 5: TAK-951 Dose 5 | Part 1 (SRD): Cohort 6: TAK-951 Dose 6 | Part 1 (SRD): Cohort 13: TAK-951 Dose 7 | Part 1 (SRD): Cohort 14: TAK-951 Dose 8 | Part 1 (SRD): Cohort 16: TAK-951 Dose 9 | Part 1 (SRD): Cohort 17: TAK-951 Dose 10 | Part 1 (SRD): Cohort 18: TAK-951 Dose 11 | Part 3 (MRD): Pooled Placebo | Part 3 (MRD): Cohort 10: TAK-951 Dose 1A | Part 3 (MRD): Cohort 11: TAK-951 Dose 2A | Part 3 (MRD): Cohort 12: TAK-951 Dose 3A | Part 3 (MRD): Cohort 20: TAK-951 Dose 4A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 25.99 (20.7 to 30.2) | 26.08 (21.2 to 30.4) | 26.32 (22.2 to 29.3) | 23.43 (19.7 to 26.8) | 23.90 (20.3 to 27.0) | 24.42 (21.5 to 29.9) | 23.88 (18.2 to 28.8) | 25.23 (20.8 to 28.7) | 26.43 (23.7 to 28.6) | 26.07 (20.7 to 28.6) | 25.77 (20.9 to 27.6) | 25.20 (18.9 to 28.0) | 24.25 (21.2 to 30.3) | 25.68 (19.9 to 29.8) | 26.17 (24.8 to 28.3) | 25.00 (21.8 to 29.0) | 26.32 (24.0 to 29.1) | 27.27 (24.8 to 30.2) | 25.41 (18.2 to 30.4) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment? commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2019 to primary completion in Nov 2020, 19 months.
Results were first posted in Sep 2023, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TAK-951